利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.02 秒)

    Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
    2.
    发明申请
    Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity 审中-公开
    抗CD3和抗原特异性免疫治疗治疗自身免疫

    公开(公告)号：US20070190045A1

    公开(公告)日：2007-08-16

    申请号：US11498381

    申请日：2006-08-03

    申请人： Kevan Herold ,  Matthias Von Herrath ,  Jeffrey Bluestone

    发明人： Kevan Herold ,  Matthias Von Herrath ,  Jeffrey Bluestone

    IPC分类号： A61K39/395 ,  A61K38/20 ,  A61K39/00

    CPC分类号： C07K16/2809 ,  A61K39/39541 ,  A61K2039/505 ,  C07K2317/52 ,  A61K2300/00

    摘要： The invention provides methods for treating autoimmunity and for reestablishing tolerance. The methods involve the coadministration of anti-CD3 antibodies and self-antigens. The coadministration has the potential to provide a synergistic effect of protecting or reducing autoaggressive immune processes and/or of reestablishing tolerance towards self-antigens. An underlying rationale behind the methods is that the administration of self-antigens together with anti-CD3 antibodies can alter the response to those self-antigens and prevent progression of autoimmunity. By rechallenging with the autoantigens and stimulating the non-pathogenic response, the blockade of the autoimmune process can be maintained. Preclinical evidence provided herein shows that the combination of anti-CD3 and autoantigen is synergistic in reversing autoimmune diabetes, and therefore, suggests that combination therapy of anti-CD3 and self-antigen may provide synergistic protection in reversing other autoimmune disorders.

    摘要翻译： 本发明提供了治疗自身免疫和重建耐受性的方法。 该方法涉及抗CD3抗体和自身抗原的共同给药。 共同行政有潜力提供保护或减少自身侵袭性免疫过程和/或重新建立对自身抗原的耐受性的协同效应。 方法背后的一个根本原因是自身抗原与抗CD3抗体的联合可以改变对这些自身抗原的反应并阻止自身免疫的进展。 通过与自身抗原反应并刺激非致病反应，可以保持自身免疫过程的封锁。 本文提供的临床前证据表明，抗CD3和自身抗原的组合在逆转自身免疫性糖尿病中具有协同作用，因此，表明抗CD3和自身抗原的联合治疗可提供逆转其他自身免疫性疾病的协同保护。